Cargando…
Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy
Introduction: Erythropoietin producing hepatocyte receptor A2 (EphA2) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation. Based on its high expression in castration-resistant prostate cancer (CRPC), we herein develop a CRISPR-Cas9-ba...
Autores principales: | Wei, Chao-Gang, Zhang, Rui, Wei, Lan-Yi, Pan, Peng, Zu, He, Liu, Ya-Zhen, Wang, Yong, Shen, Jun-Kang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794984/ https://www.ncbi.nlm.nih.gov/pubmed/36588949 http://dx.doi.org/10.3389/fbioe.2022.1078342 |
Ejemplares similares
-
Editorial: Current approaches to CRISPR/Cas9 delivery
por: Uludağ, Hasan, et al.
Publicado: (2022) -
CRISPR/Cas systems: Delivery and application in gene therapy
por: Huang, Jie, et al.
Publicado: (2022) -
CRISPR/Cas9-mediated genome editing in vancomycin-producing strain Amycolatopsis keratiniphila
por: Hu, Mengyi, et al.
Publicado: (2023) -
Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation
por: Foley, Ruth A., et al.
Publicado: (2022) -
Off-target effects in CRISPR/Cas9 gene editing
por: Guo, Congting, et al.
Publicado: (2023)